Tocilizumab, a recent FDA-approved humanized mAb used to treat autoimmune and inflammatory diseases, has been proposed to inhibit the trastuzumab-resistant HER2(+) breast cancer [42]. The gene discussed is ERBB2; the disease is breast carcinoma.